orgogozo Jun 20, 2014:

Squelette substitué = squelette modifié par des substitutions de radicaux

orgogozo Jun 19, 2014:

@PLR Cancer treatment and diagnosis[edit]DOTA is used as part of some cancer therapies, where it functions as a chelating agent for the radioisotope 90Y3+. DOTA can be conjugated to monoclonal antibodies by attachment of one of the four carboxyl groups as an amide. The remaining three carboxylate anions are available for binding to the yttrium ion. The modified antibody accumulates in the tumour cells, concentrating the effects of the radioactivity of 90Y. Drugs containing this module receive an International Nonproprietary Name ending in tetraxetan:[5]

Yttrium (90Y) clivatuzumab tetraxetan
Yttrium (90Y) tacatuzumab tetraxetan
DOTA can also be linked to molecules that have affinity for various structures. The resulting compounds are used with a number of radioisotopes in cancer therapy and diagnosis (for example in positron emission tomography).

Affinity for somatostatin receptors, which are found on neuroendocrine tumours:[6]
DOTATOC, DOTA-(Tyr3)-octreotide or edotreotide
DOTA-TATE or DOTA-(Tyr3)-octreotate
Affinity for the proteins streptavidin and avidin, which can be targeted at tumours by aid of monoclonal antibodies:[7]
DOTA-biotin